Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2024 06:33 ET | Source: Novonesis (Novozymes A/S)

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
September 06, 2024 02:51 ET | Source: Novozymes A/S

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
September 05, 2024 07:07 ET | Source: Novozymes A/S

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
September 02, 2024 12:36 ET | Source: Novozymes A/S

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_31_Trading_By_Management ...
September 02, 2024 12:27 ET | Source: Novozymes A/S

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_30_Trading_By_Management ...
August 30, 2024 06:17 ET | Source: Novozymes A/S

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_29_Trading_By_Management ...
August 29, 2024 09:17 ET | Source: Novozymes A/S

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
August 27, 2024 10:34 ET | Source: Novozymes A/S

Novonesis delivers strong half-year results and increases full-year outlook

In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic...
August 27, 2024 10:30 ET | Source: Novozymes A/S

Interim Report H1 2024

H1 organic pro forma sales growth at 7%, with pro forma adjusted EBITDA margin at 35.3%. Full-year outlook increased. H1 organic pro forma sales growth of 7% and 8% on IFRS reported basis. Q2...
August 27, 2024 10:29 ET | Source: Novozymes A/S

Novonesis increases outlook for full year 2024

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.The 2024 outlook...